Jianfeng Zhou
Huazhong University of Science and Technology
314 Papers
852 Citations
Jianfeng Zhou is an academic researcher from Huazhong University of Science and Technology. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 34, co-authored 295 publications. Previous affiliations of Jianfeng Zhou include Peking Union Medical College & Qinghai University.
Chat about Author
Papers
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
Yang Cao,Jia Wei,Liang Zou,Tiebin Jiang,Gaoxiang Wang,Liting Chen,Liang Huang,Fankai Meng,Lifang Huang,Na Wang,Xiaoxi Zhou,Hui Luo,Zekai Mao,Xing Chen,Jungang Xie,Jing Liu,Hui Cheng,Jianping Zhao,Gang Huang,Wei Wang,Jianfeng Zhou +20 more
TL;DR: Treatment with ruxolitinib plus SoC was not associated with significantly accelerated clinical improvement in severe patients with COVID-19, although ruxolinib recipients had a numerically faster clinical improvement.
475
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
TL;DR: Mechanisms and predictive biomarkers for PD-1 blockade immunotherapy, treatment-related adverse events, hyperprogression, and combination therapies are discussed in the context of B-cell lymphomas.
388
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.
Yuankai Shi,Hang Su,Yongping Song,Wenqi Jiang,Xiuhua Sun,Wenbin Qian,Wei Zhang,Yuhuan Gao,Zhengming Jin,Jianfeng Zhou,Chuan Jin,Liqun Zou,Lugui Qiu,Wei Li,Jianmin Yang,Ming Hou,Shan Zeng,Qingyuan Zhang,Jianda Hu,Hui Zhou,Yan Xiong,Peng Liu +21 more
TL;DR: Sintilimab could be a new treatment option for patients with relapsed or refractory classical Hodgkin lymphoma in China and is registered with ClinicalTrials.gov, number NCT03114683.
218
Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation.
TL;DR: Hoechst 33258 staining showed that curcumin could induce Raji cell apoptosis, andCurcumin, as a new member of the histone deacetylase inhibitors, can inhibit the expression of class I HDACs (HDAC1, HDAC3, and HDAC8), and can increase theexpression of Ac-histone H4 in Raji cells.
Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer.
Qinglei Gao,Zongyuan Yang,Sen Xu,Xiaoting Li,Xin Yang,Ping Jin,Yi Liu,Xiaoshui Zhou,Taoran Zhang,Cheng Gong,Xiao Wei,Dan Liu,Chaoyang Sun,Gang Chen,Junbo Hu,Li Meng,Jianfeng Zhou,Kenjiro Sawada,Robert Fruscio,Thomas W. Grunt,Jörg Wischhusen,Víctor Manuel Vargas-Hernández,Bhavana Pothuri,Robert L. Coleman +23 more
TL;DR: These findings identify a specialized MU architecture that amplifies the tumor–stroma interaction and promotes transcoelomic metastasis in HGSOC, providing the basis for stromal fibroblast-oriented interventions in hampering OC peritoneal propagation.